Genocea Biosciences Inc (GNCA) Receives Consensus Recommendation of “Buy” from Analysts

Genocea Biosciences Inc (NASDAQ:GNCA) has earned an average rating of “Buy” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $4.00.

Several analysts recently commented on the stock. HC Wainwright set a $5.00 price target on shares of Genocea Biosciences and gave the stock a “buy” rating in a report on Wednesday, November 7th. Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Monday, November 5th.

Shares of GNCA opened at $0.57 on Friday. Genocea Biosciences has a one year low of $0.49 and a one year high of $1.39. The stock has a market capitalization of $49.38 million, a price-to-earnings ratio of -0.29 and a beta of 1.14. The company has a quick ratio of 4.01, a current ratio of 4.01 and a debt-to-equity ratio of 1.91.

Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Thursday, November 1st. The biotechnology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. As a group, analysts anticipate that Genocea Biosciences will post -0.45 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in shares of Genocea Biosciences by 169.1% during the first quarter. BlackRock Inc. now owns 3,960,353 shares of the biotechnology company’s stock worth $4,159,000 after purchasing an additional 2,488,540 shares during the period. Paloma Partners Management Co acquired a new stake in shares of Genocea Biosciences during the second quarter worth approximately $343,000. California State Teachers Retirement System boosted its holdings in shares of Genocea Biosciences by 166.6% during the first quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 78,469 shares during the period. DRW Securities LLC acquired a new stake in shares of Genocea Biosciences during the second quarter worth approximately $205,000. Finally, Fosun International Ltd acquired a new stake in shares of Genocea Biosciences during the third quarter worth approximately $323,000. Institutional investors and hedge funds own 60.86% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Featured Article: Price to Earnings Ratio (PE)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply